Phase 3 trial of eribulin versus dacarbazine in leiomyosarcoma and liposarcoma - European Medical Journal

Phase 3 trial of eribulin versus dacarbazine in leiomyosarcoma and liposarcoma

Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Patrick Schöffski, MD, of University Hospitals Leuven, Leuven, Belgium, discusses the results of a randomised, open-label, multicentre, phase 3 trial of the microtubule dynamics inhibitor, eribulin, versus dacarbazine for the treatment of patients with advanced liposarcoma or leiomyosarcoma.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now